Skip to content
Homepage
Author:
UroGen Pharma Ltd.
Posted Date:
August 18, 2026
UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC
UroGen Pharma Ltd.
August 18, 2026
UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights
UroGen Pharma Ltd.
August 5, 2026
UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights
UroGen Pharma Ltd.
August 5, 2026
UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026
UroGen Pharma Ltd.
July 29, 2026
UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103
UroGen Pharma Ltd.
July 15, 2026
UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103
UroGen Pharma Ltd.
July 15, 2026
UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer
UroGen Pharma Ltd.
July 8, 2026
